Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Treatment of parkinson's disease ata young age

https://doi.org/10.14412/2074-2711-2010-93

Full Text:

Abstract

The paper considers the specific features of the diagnosis and treatment of parkinsonism in young and middle-aged patients. It is stressed that early-onset Parkinson's disease (PD) shows a number of the specific features of the mechanism responsible for the development, clinical picture, and course, as well as a response to antiparkinsonian agents, and prognosis. Indications for the use of different groups of antiparkinsonian drugs and the basic principles of management in young and middle-aged patients are discussed. Emphasis is laid on the key role of non-ergoline dopamine receptor agonists in the treatment of patients with PD. Approaches to correcting the non-motor symptoms of PD and current indications for neurosurgical treatment are considered.

References

1. <div><p>Иллариошкин С.Н. Основные принципы терапии болезни Паркинсона. РМЖ 2004;12(10):604-8.</p><p>Нодель М.Р., Русакова И.М., Яхно Н.Н. Клиническая оценка нарушений сна и бодрствования при болезни Паркинсона. Неврол журн 2010;2:19-25.</p><p>Hall E.D., Andrus P.K., Oostveen J.A. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postis-chemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996;742(1-2):80-8.</p><p>Parkinson Study Group. Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease. A Randomized Controlled Trial. JAMA 2000;284:1931-8.</p><p>Артемьев Д.В. Современные принципы терапии болезни Паркинсона. Трудный пациент 2005;3(12):10-5.</p><p>Hauser R.A., McDermott M.P., Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63(12):1756-60.</p><p>Яхно Н.Н., Нодель М.Р., Федорова Н.В. и др. Эффективность и переносимость прамипексола (мирапекса) при продолжительной терапии у пациентов с болезнью Паркинсона. Неврол журн 2004;9(3):25-30.</p><p>Нодель М.Р., Яхно Н.Н. Двигательные флуктуации и дискинезии при болезни Паркинсона: новые возможности терапии. Неврол журн 2007;2:26-33.</p><p>Левин О.С. Агонисты дофаминовых рецепторов в лечении болезни Паркинсона. Леч нервн бол 2003;4(1):14-7.</p><p>Hristova A.H., Koller W.C. Early Parkinson's disease: what is the best approach to treatment. Drugs Aging 2000;17(3):165-81.</p><p>Reichmann H., Brecht M.H., Köster J. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 2003;17(13):965-73.</p><p>Lemke M.R., Brecht H.M., Kö ester J. at al. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 2006;248(1-2):266-70.</p><p>Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 2002;287:1653-61.</p><p>Нодель М.Р., Яхно Н.Н. Мирапекс (прамипексол) в лечении недвигательных нарушений при болезни Паркинсона. Журн неврол и психиатр им. С.С. Корсакова 2008;5:32-8.</p><p>Федорова Н.В., Кулуа Т.К. Опыт применения прамипексола в лечении болезни Паркинсона. Consilium medicum 2007; 9(2):103-7.</p><p>Ravina B., Camicioli R., Como P.G. at al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007;69(4):342-7.</p><p>Голубев В.Л., Левин Я.И., Вейн А.М. Болезнь Паркинсона и синдром паркинсонизма. М.: Мед-пресс, 1999;415 с.</p><p>Goetz C.G., Poewe W., Rascol O. et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Dis 2005;20:523-39.</p></div><br />


For citation:


Artemyev D.V. Treatment of parkinson's disease ata young age. Neurology, Neuropsychiatry, Psychosomatics. 2010;2(3):6-11. (In Russ.) https://doi.org/10.14412/2074-2711-2010-93

Views: 501


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)